⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Form 8-K
sec.gov
APVO
Form 8-K
sec.gov
APVO
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
accessnewswire.com
APVO
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
accessnewswire.com
APVO